Phoenix strengthen its team

Dr. Spiros Kotopoulis joins the Phoenix management team as VP Technology Development.

CEO Per Sontum: “We are delighted to announce that Dr. Kotopoulis joins our team. Having worked with Spiros as an academic collaborator since the incorporation of the company, we know he will add a vital strength to our capabilities. He has been working across the board within ultrasound mediated drug delivery for a more than decade, including transducer development, pre-clinical and clinical studies hence, his experience is perfectly matched to our needs for the coming development phase of ACT®”.

Dr. Spiros Kotopoulis, BEng (Hons), PhD (Engineering) has 10+ years of experience working in the field of ultrasound and microbubble enhanced drug delivery. He completed his PhD in 2011 at the University of Hull (UK) in the field of Biomedical Ultrasonics and continued his research at Haukeland University Hospital in Bergen, Norway. Throughout his career he has worked on, and lead, a multitude of projects all focused on microbubble enhanced therapy; including microbubble and transducer development, in vitro optimisation and evaluation, preclinical and clinical studies. Dr. Kotopoulis also holds an Assoc. Professorship at University of Bergen.

Phoenix Solutions AS completes its Series A financing:

The Board of Directors of Phoenix Solutions is pleased to announce that the company has completed a series A financing led by a small group of healthcare angel investors. CEO Per Sontum; "We are very pleased to announce this first round of financing. This funding will give us the ability to reach a key developmental milestone for our preclinical work in pancreatic cancer ".